4-氯-8-甲基喹啉 | 18436-73-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-8-甲基喹啉
• 英文名称: 4-chloro-8-methylquinoline
• CAS: 18436-73-2
• 化学式: C₁₀H₈ClN
• mdl: MFCD00272330
• 分子量: 177.633
• InChiKey: PGDPMZFATHZAIQ-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R41,R36
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  常温下应密闭避光保存，并保持通风和干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-8-methylquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-8-methylquinoline
CAS number: 18436-73-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H8ClN
Molecular weight: 177.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-8-甲基喹啉 在 肼 作用下， 以 二乙二醇 为溶剂， 反应 1.0h， 生成 4-肼基-8-甲基喹啉
  参考文献：
  名称：

  Synthesis andin vitroEvaluation of New Benzenesulfonamides as Antileishmanial Agents

  摘要：

  This paper describes the synthesis and the antileishmanial activity of new pyrazolyl benzenesulfonamide derivatives. These were elucidated by spectrometric methods. Some compounds showed a significant in vitro activity against Leishmania amazonensis, highlighting the derivative 1e. These pyrazolyl benzenesulfonamide derivatives did not show any toxicity in murine macrophage.

  DOI：

  10.5935/0103-5053.20140062
• 作为产物：
  描述：

  4-羟基-8-甲基喹啉 在 三氯氧磷 作用下， 反应 1.0h， 生成 4-氯-8-甲基喹啉
  参考文献：
  名称：

  4-[(Quinolin-4-yl)amino]苯甲酰胺衍生物作为新型抗流感病毒药物的设计、合成、分子对接分析和生物学评价

  摘要：

  本研究设计合成了一系列4-[(quinolin-4-yl)amino]苯甲酰胺衍生物作为新型抗流感药物。进行细胞毒性试验、细胞病变效应试验和噬斑抑制试验以评估目标化合物的抗流感病毒 A/WSN/33 (H1N1) 活性。目标化合物G07在细胞病变效应试验 (EC 50 = 11.38 ± 1.89 µM) 和噬菌斑抑制试验 (IC 50 = 0.23 ± 0.15 µM)中均表现出显着的抗流感病毒 A/WSN/33 (H1N1) 活性。G07对其他三种不同的流感病毒株 A/PR/8 (H1N1)、A/HK/68 (H3N2) 和乙型流感病毒也表现出显着的抗流感病毒活性。根据核糖核蛋白重组试验结果，G07与核糖核蛋白相互作用良好，在100 µM时抑制率为80.65%。此外，根据最佳药效团 Hypo1 预测的 PA-PB1 抑制活性， G07表现出显着的活性靶标 RNA 聚合酶 PA-PB1

  DOI：

  10.3390/ijms23116307

文献信息

• Ru(II)/Rh(III)-Catalyzed C(sp³)–C(sp³) Bond Formation through C(sp³)–H Activation: Selective Linear Alkylation of 8-Methylquinolines and Ketoximes with Olefins
  作者：Rohit Kumar、Rakesh Kumar、Diksha Parmar、Shiv Shankar Gupta、Upendra Sharma

  DOI：10.1021/acs.joc.9b03257

  日期：2020.1.17

  Herein, [RuCl2(p-cymene)]2/[Cp*RhIIICl2]2-catalyzed direct alkylation of C(sp3)-H bond of 8-methylquinolines with olefins (acrylates, styrenes, and aliphatic) is reported. The alkylation also proceeds with other conjugated systems such as malemides and α,β-unsaturated ketones. The reaction is highly regioselective, forms only a linear product, and tolerates a variety of functional groups on quinoline

  在本文中，报道了[RuCl 2（对异丙基）] 2 / [Cp * RhIIICl 2] 2催化的8-甲基喹啉的C（sp3）-H键与烯烃（丙烯酸酯，苯乙烯和脂肪族）的直接烷基化。烷基化还与其他共轭体系（例如马来酰亚胺和α，β-不饱和酮）一起进行。该反应是高度区域选择性的，仅形成线性产物，并且耐受喹啉和烯烃部分上的多种官能团。为了初步了解反应途径，已经进行了对照实验，氘标记和动力学研究。该反应可能在氧化还原中性条件下通过五元金属环进行。还已经进行了烷基化产物的多样化和（-）-桑托宁的酮肟衍生物的后期官能化，以证明所开发方法的适用性。
• [EN] N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS N-HÉTÉROARYLÉS AYANT UNE UNITÉ PONTANTE CYCLIQUE POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：INTERVET INT BV

  公开号：WO2012041872A1

  公开（公告）日：2012-04-05

  This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of the N-heteroaryl compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  这项发明涉及某些N-杂环芳基化合物，通常用作药物，更具体地用作动物药物。该药物可以优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。该发明还涉及利用这些化合物制备药物和治疗方法，包括将这些化合物用于需要治疗的动物的给药。此外，该发明还涉及N-杂环芳基化合物的制备。此外，该发明还涉及包含这些化合物的药物组合物和试剂盒。
• [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS D'AKT3
  申请人：GEORGIAMUNE LLC

  公开号：WO2021226517A1

  公开（公告）日：2021-11-11

  Compounds of Formula la, lb, or Ic,, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

  公式Ia、Ib或Ic的化合物被描述，其中各种取代基在此处被定义。这些化合物可以在体外或体内调节Akt3的性质或效应，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了使用这些化合物或组合物的药物组合物和使用这些化合物或组合物，单独或与其他药剂或组合物结合在预防或治疗各种疾病方面的方法。
• [EN] QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS<br/>[FR] DERIVES DE QUINOLYLE AMIDE ANTAGONISTES DE CCR-5
  申请人：SCHERING AG

  公开号：WO2004113323A1

  公开（公告）日：2004-12-29

  The present invention relates to a series of compounds which are CCR-5 receptor antagonists of the general formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein.

  本发明涉及一系列化合物，其为一般式(I)的CCR-5受体拮抗剂，或其药学上可接受的盐，其中变量在此处定义。
• [EN] CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE CHROMANE, D'ISOCHROMANE ET DE DIHYDROISOBENZOFURANE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR2, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2018063955A1

  公开（公告）日：2018-04-05

  The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from (II), (III), (IV), and (V), and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild congnitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了某些取代的色苷、异色苷和二氢异苯并呋喃化合物的化学结构（I），或其药学上可接受的盐，其中环A是从（II）、（III）、（IV）和（V）中选择的基团，环B、n、R1、R2、R2A、R3和R3A如本文所定义。本发明的化合物可用作mGluR2抑制剂，或mGluR2负向变构调节剂（NAMs），并可用于治疗mGluR2-NAM受体参与的疾病或障碍的方法，如阿尔茨海默病、认知障碍、轻度认知障碍、精神分裂症和其他情绪障碍、疼痛障碍和睡眠障碍，通过向患者投予本发明化合物或其药学上可接受的盐的治疗有效量。本发明还涉及含有本发明化合物或其药学上可接受的盐（可选地与一个或多个额外活性成分组合）和药学上可接受的载体的药物组合物，以及在治疗这些疾病中使用本发明的化合物和药物组合物。